BLD-2660

DRUG4 trials

Sponsors

Blade Therapeutics

Conditions

Covid19FibrosisIdiopathic Pulmonary FibrosisSars-CoV-2

Phase 1

First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis

CompletedNCT03559166

Blade TherapeuticsFibrosis

Start: 2018-07-11End: 2019-10-04Updated: 2020-03-19

Healthy Volunteer Study Comparing Tablet and Capsule Formulations

WithdrawnNCT04001998

Blade TherapeuticsFibrosis

Start: 2021-02-28End: 2021-07-31Updated: 2020-10-30

Phase 2

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

WithdrawnNCT04244825

Blade TherapeuticsIdiopathic Pulmonary Fibrosis

Start: 2019-12-15End: 2020-11-05Updated: 2021-03-04

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

CompletedNCT04334460

Blade TherapeuticsCovid19, Sars-CoV-2

Start: 2020-05-04End: 2021-06-21Updated: 2022-04-06